ClinicalTrials.gg
CompletedNCT00844805INFASTUpdated Apr 12, 2017Results posted

Infliximab for Treatment of Axial Spondyloarthritis (P05336 AM1)

A Phase 3 interventional study of Infliximab and Placebo in Ankylosing Spondylitis and Axial Spondyloarthritis, sponsored by Merck Sharp & Dohme LLC. Completed. Open to participants aged 18 Years to 48 Years. Per ClinicalTrials.gov, last updated 2017-04-12.

Sponsored by Merck Sharp & Dohme LLC (part of Merck & Co., Inc) · Phase 3, Interventional, and Treatment

How we know

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 3
Study type
Interventional
Enrollment
158
Allocation
Randomized
Ages
18 Years to 48 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-20

Among 20 studies testing infliximab in Spondylitis, Ankylosing — 1 open to participants now, 1 under way, none of them phase 3. Infliximab · Spondylitis, Ankylosing.

Enrollment
7th of 20
158 · median 85
Started
2009
the only one that year
Phase 3
5 of 20
none open now
Registered
11th of 20
by date
Lead sponsor
7 of 20
Merck Sharp & Dohme LLC

Among the 20 studies testing infliximab in Spondylitis, Ankylosing, this one is the 7th largest by enrollment, is the only one that started in 2009, is one of 5 in phase 3, and was the 11th registered.

Spondylitis, Ankylosing

534 studies on the registry are indexed under Spondylitis, Ankylosing; 99 are open to participants now.

Browse Spondylitis, Ankylosing studies →

Open to participants now

1 of the 20 studies testing infliximab in Spondylitis, Ankylosing is open now, in 1 country. Recruiting first, the newest first:

By country, each count listing its studies:

About infliximab

Infliximab: first FDA approval 1998 (REMICADE), first EMA approval 1999. What it is approved for, and how studies give it, is on its page →

Who these studies take

Of the 62 Spondylitis, Ankylosing studies recruiting now, 24 (39%) set no upper age limit and 32 (52%) stop at 75 or younger; 10 take children under 18; 15 take healthy volunteers.

This study: 18 Years to 48 Years · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 20 studies testing infliximab in Spondylitis, Ankylosing, or all of them as a file.
02

Study summary

The primary objective of this study was to assess the proportion of participants in the infliximab plus naproxen arm versus the placebo plus naproxen arm, in a population of participants with moderate-to-severe active axial spondyloarthritis and disease duration of ≤3 years, who achieve the Assessment in Ankylosing Spondylitis (ASAS) partial remission criteria.

Read the detailed description

In the 28-week treatment phase, participants were randomized to receive either infliximab plus naproxen or placebo plus naproxen.

After 28-weeks of treatment, participants that achieved partial remission in the treatment phase were randomized to continued treatment with naproxen or to receive no treatment and were followed for an additional 24 weeks (follow-up phase).

03

Conditions studied

  • Ankylosing Spondylitis
  • Axial Spondyloarthritis
04

Who can participate

Ages eligible
18 Years to 48 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

Participant must:

  • be 18 to 48 years of age
  • have diagnosis of active axial spondyloarthritis, with disease duration of less than or equal to 3 years.
  • have active disease during trial enrollment
  • have limited treatment history for axial spondyloarthritis (must meet certain criteria)
  • agree to an acceptable method of (for women of and all men)
  • must meet certain tuberculosis screening requirements
  • must meet certain laboratory screening safety requirements
  • have an x-ray of the sacroiliac joints available from within the previous 12 months (or have one performed during the Screening visit if site is outside of Germany).

Exclusion criteria

Exclusion Criteria:

Participant will be excluded:

  • for certain medical conditions and/or recent history of certain medical disorders
  • for current or recent treatment with certain other medications and certain vaccinations.
  • for being a woman who is breastfeeding, pregnant, or intending to become pregnant.
  • if known to have had a substance abuse problem within the previous 3 years prior to screening.
  • if currently participating in any other clinical study.
  • for other administrative reasons.
Terms in these criteria, in plain language(2)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

Childbearing potential

Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).

Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.

05

Study design

Phase
Phase 3
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Quadruple (Participant, Care provider, Investigator, Outcomes assessor)
Enrollment
158 participants (actual)

Study arms

  • Experimental
    Infliximab + Naproxen

    Infliximab administered at a dose of 5 mg/kg intravenously on Day 1 of Weeks 0, 2, 6, 12, 18, and 24, combined with naproxen administered at a daily dose of 1000 mg for 28 weeks during the 28-week treatment phase.

    Drug: Infliximab · Drug: Naproxen

  • Placebo comparator
    Placebo + Naproxen

    Placebo administered intravenously on Day 1 at Weeks 0, 2, 6, 12, 18, and 24, combined with naproxen administered at a daily dose of 1000 mg for 28 weeks, during the 28-week treatment phase.

    Drug: Placebo · Drug: Naproxen

  • Experimental
    Naproxen Only (Follow-Up)

    For participants who achieved partial remission during 28-week treatment phase, naproxen was continued at a daily dose of 1000 mg administered orally for an additional 24 weeks in the follow-up phase.

    Drug: Naproxen

  • No intervention
    No Treatment (Follow-Up)

    For participants who achieved partial remission during Treatment phase, no treatment was administered for an additional 24 weeks in the follow-up phase.

Interventions

  • Also known as: Remicade, SCH 215596

  • DrugPlacebo
  • Also known as: Naprosyn

06

What researchers measure

Primary outcomes

  1. Number of Participants Achieving the Assessment in Ankylosing Spondylitis (ASAS) Partial Remission Criteria at Week 28

    ASAS domains were measured on a visual analog scale (VAS) of 0 to 100 mm (with 0 being the very best situation and 100 being the very worst situation). ASAS partial remission criteria is defined as reaching ≤20 mm in all 4 ASAS domains (i.e., patient global assessment, total back pain, function, and inflammation).

    Time frame: Week 28

Secondary outcomes

  1. Number of Participants Maintaining the ASAS Partial Remission Criteria at Week 52 By Treatment Assignment in the Follow-Up Phase

    ASAS domains were measured on a VAS of 0 to 100 mm (with 0 being the very best situation and 100 being the very worst situation). ASAS partial remission criteria is defined as reaching ≤20 mm in all 4 ASAS domains (i.e., patient global assessment, total back pain, function, and inflammation).

    Time frame: Week 52

  2. Percentage of Participants Maintaining the ASAS Partial Remission Criteria at Week 52 By Treatment Assignment in the Treatment Phase

    ASAS domains were measured on a VAS of 0 to 100 mm (with 0 being the very best situation and 100 being the very worst situation). ASAS partial remission criteria is defined as reaching ≤20 mm in all 4 ASAS domains (i.e., patient global assessment, total back pain, function, and inflammation).

    Time frame: Week 52

  3. Change From Baseline of Berlin Magnetic Resonance Imaging (MRI) Spine Overall Score at Week 28

    MRI scans (T1 for chronic changes and short tau inversion recovery \[STIR\] for active changes) of the whole spine was performed to determine the Berlin MRI Spine Score. The Berlin MRI scoring for the spine was assessed on a scale of 0 (best) to 3 (worst) for a maximum total score of 69, with 0 = no inflammatory lesions; 1 = minor bone marrow edema; 2 = moderate bone marrow edema; 3 = major bone marrow edema; or N = non readable.

    Time frame: Baseline, Week 28

  4. Change From Baseline in the Sacroiliac Overall Score at Week 28

    Each sacroiliac joint was divided into four quadrants. An activity score of 0 (best) to 3 (worst) was assessed for every quadrant of the left and right sacroiliac joint separately for a total maximum score of 24, with with 0 = no inflammatory lesions; 1 = minor bone marrow edema; 2 = moderate bone marrow edema; 3 = major bone marrow edema; or N = non readable.

    Time frame: Baseline, Week 28

  5. Change From Baseline of Berlin MRI Spine Overall Score at Week 52

    MRI scans (T1 for chronic changes and STIR for active changes) of the whole spine was performed to determine the Berlin MRI Spine Score. The Berlin MRI scoring for the spine was assessed on a scale of 0 (best) to 3 (worst) for a maximum total score of 69, with 0 = no inflammatory lesions; 1 = minor bone marrow edema; 2 = moderate bone marrow edema; 3 = major bone marrow edema; or N = non readable.

    Time frame: Baseline, Week 52

  6. Change From Baseline in the Sacroiliac Overall Score at Week 52

    Each sacroiliac joint was divided into four quadrants. An activity score of 0 (best) to 3 (worst) was assessed for every quadrant of the left and right sacroiliac joint separately for a total maximum score of 24, with with 0 = no inflammatory lesions; 1 = minor bone marrow edema; 2 = moderate bone marrow edema; 3 = major bone marrow edema; or N = non readable.

    Time frame: Baseline, Week 28

  7. Number of Participants With Complete Absence of Active Inflammatory Lesions at the Spine at Treatment Week 28

    MRI scans (T1 for chronic changes and STIR for active changes) of the whole spine was performed to determine the Berlin MRI Spine Score. The Berlin MRI scoring for the spine was assessed on a scale of 0 (best) to 3 (worst) for a maximum total score of 69, with 0 = no inflammatory lesions; 1 = minor bone marrow edema; 2 = moderate bone marrow edema; 3 = major bone marrow edema; or N = non readable. Complete absence of active inflammatory lesions was defined as a Berlin MRI Score = 0.

    Time frame: Week 28

  8. Number of Participants With Complete Absence of Active Inflammatory Lesions at the Sacroiliac Joint at Treatment Week 28

    Each sacroiliac joint was divided into four quadrants. An activity score of 0 (best) to 3 (worst) was assessed for every quadrant of the left and right sacroiliac joint separately for a total maximum score of 24, with with 0 = no inflammatory lesions; 1 = minor bone marrow edema; 2 = moderate bone marrow edema; 3 = major bone marrow edema; or N = non readable. Complete absence of active inflammatory lesions at the sacroiliac joints was defined as a Score = 0.

    Time frame: Week 28

  9. Number of Participants With Complete Absence of Active Inflammatory Lesions at the Spine and Sacroiliac Joint at Treatment Week 28

    MRI scans (T1 for chronic changes and STIR for active changes) of the whole spine was performed to determine the Berlin MRI Spine Score. The Berlin MRI scoring for the spine was assessed on a scale of 0 (best) to 3 (worst) for a maximum total score of 69, with 0 = no inflammatory lesions; 1 = minor bone marrow edema; 2 = moderate bone marrow edema; 3 = major bone marrow edema; or N = non readable. Complete absence of active inflammatory lesions was defined as a Berlin MRI Score = 0. Each sacroiliac joint was divided into four quadrants. An activity score of 0 (best) to 3 (worst) was assessed for every quadrant of the left and right sacroiliac joint separately for a total maximum score of 24, with with 0 = no inflammatory lesions; 1 = minor bone marrow edema; 2 = moderate bone marrow edema; 3 = major bone marrow edema; or N = non readable. Complete absence of active sacroiliac inflammatory lesions was defined as a Score = 0.

    Time frame: Week 28

  10. Number of Participants With Complete Absence of Active Inflammatory Lesions at the Spine at Treatment Week 52

    MRI scans (T1 for chronic changes and STIR for active changes) of the whole spine was performed to determine the Berlin MRI Spine Score. The Berlin MRI scoring for the spine was assessed on a scale of 0 (best) to 3 (worst) for a maximum total score of 69, with 0 = no inflammatory lesions; 1 = minor bone marrow edema; 2 = moderate bone marrow edema; 3 = major bone marrow edema; or N = non readable. Complete absence of active inflammatory lesions was defined as a Berlin MRI Score = 0.

    Time frame: Week 52

  11. Number of Participants With Complete Absence of Active Inflammatory Lesions at the Sacroiliac Joint at Treatment Week 52

    EaEach sacroiliac joint was divided into four quadrants. An activity score of 0 (best) to 3 (worst) was assessed for every quadrant of the left and right sacroiliac joint separately for a total maximum score of 24, with with 0 = no inflammatory lesions; 1 = minor bone marrow edema; 2 = moderate bone marrow edema; 3 = major bone marrow edema; or N = non readable. Complete absence of active sacroiliac inflammatory lesions was defined as a Score = 0.

    Time frame: Week 52

  12. Number of Participants With Complete Absence of Active Inflammatory Lesions at the Spine and Sacroiliac Joint at Treatment Week 52

    MRI scans (T1 for chronic changes and STIR for active changes) of the whole spine was performed to determine the Berlin MRI Spine Score. The Berlin MRI scoring for the spine was assessed on a scale of 0 (best) to 3 (worst) for a maximum total score of 69, with 0 = no inflammatory lesions; 1 = minor bone marrow edema; 2 = moderate bone marrow edema; 3 = major bone marrow edema; or N = non readable. Complete absence of active spinal inflammatory lesions was defined as a Berlin MRI Score = 0. Each sacroiliac joint was divided into four quadrants. An activity score of 0 (best) to 3 (worst) was assessed for every quadrant of the left and right sacroiliac joint separately for a total maximum score of 24, with with 0 = no inflammatory lesions; 1 = minor bone marrow edema; 2 = moderate bone marrow edema; 3 = major bone marrow edema; or N = non readable. Complete absence of active sacroiliac inflammatory lesions was defined as a Score = 0.

    Time frame: Week 52

  13. Median Duration of Maintaining ASAS Partial Remission in the Follow-Up Phase

    ASAS domains were measured on a VAS of 0 to 100 mm (with 0 being the very best situation and 100 being the very worse situation). ASAS partial remission criteria is defined as reaching ≤20 mm in all 4 ASAS domains (i.e., patient global assessment, total back pain, function, and inflammation).

    Time frame: Week 52

  14. Number of Participants Who Achieved ASAS Partial Remission That Experienced Disease Flare With Naproxen Maintenance Treatment in the Follow-Up Phase

    The Bath Ankylosing Spondylitis Disease Activity Index (BASDAI) employs a VAS of 0mm (best) to 100mm (worst). Disease flare was defined as reaching a BASDAI of ≥30 mm during two consecutive visits after Week 28 until Week 52. ASAS domains were measured on a VAS of 0 to 100 mm (with 0 being the very best situation and 100 being the very worse situation). ASAS partial remission criteria was defined as reaching ≤20 mm in all 4 ASAS domains (i.e., patient global assessment, total back pain, function, and inflammation).

    Time frame: Week 52

  15. Percentage of Participants That Achieved ASAS-40 Response at Week 28 in the Treatment Phase

    ASAS domains were measured on a VAS of 0 to 100 mm (with 0 being the very best situation and 100 being the very worse situation). ASAS-40 response was defined as ASAS achieving ≥40% improvement in 3 of the 4 domains (patient global assessment, total back pain, function, and inflammation), with an absolute improvement of ≥20 mm and no deterioration in the remaining domain.

    Time frame: Week 28

  16. Percentage of Participants That Achieved ASAS-20 Response at Week 28 in the Treatment Phase

    ASAS-20 response was defined as ≥20% improvement in response according to following criteria: • An improvement of ≥20% from baseline and an absolute improvement from baseline of ≥10 mm in at least 3 of the following 4 domains (patient global assessment, pain, function,and inflammation) • Absence of deterioration from baseline (≥20% and an absolute change of ≥10 mm) in the potential remaining domain.

    Time frame: Week 28

07

Results

Posted Dec 17, 2012

Participant flow

Treatment Phase
Participant flow — Treatment Phase
MilestoneInfliximab + NaproxenPlacebo + NaproxenNaproxenNo Treatment
Started1065200
Completed964500
Not completed10700
Withdrew: Adverse event5100
Withdrew: Withdrawal by subject3400
Withdrew: Noncompliance with protocol1000
Withdrew: Did not meet protocol eligibility1200
Follow-Up Phase
Participant flow — Follow-Up Phase
MilestoneInfliximab + NaproxenPlacebo + NaproxenNaproxenNo Treatment
Started004141
Completed003232
Not completed0099
Withdrew: Adverse event0010
Withdrew: Withdrawal by subject0063
Withdrew: Noncompliance with protocol0001
Withdrew: Relapse/recurrence0024
Withdrew: Did not meet protocol eligibility0001

Outcome measures

PrimaryNumber of Participants Achieving the Assessment in Ankylosing Spondylitis (ASAS) Partial Remission Criteria at Week 28

ASAS domains were measured on a visual analog scale (VAS) of 0 to 100 mm (with 0 being the very best situation and 100 being the very worst situation). ASAS partial remission criteria is defined as reaching ≤20 mm in all 4 ASAS domains (i.e., patient global assessment, total back pain, function, and inflammation).

Time frame:
Week 28
Reported as:
Number · Participants
Number of Participants Achieving the Assessment in Ankylosing Spondylitis (ASAS) Partial Remission Criteria at Week 28
ParticipantsInfliximab + NaproxenPlacebo + Naproxen
Achieved Partial Remission6518
Did Not Achieve Partial Remission4033
SecondaryNumber of Participants Maintaining the ASAS Partial Remission Criteria at Week 52 By Treatment Assignment in the Follow-Up Phase

ASAS domains were measured on a VAS of 0 to 100 mm (with 0 being the very best situation and 100 being the very worst situation). ASAS partial remission criteria is defined as reaching ≤20 mm in all 4 ASAS domains (i.e., patient global assessment, total back pain, function, and inflammation).

Time frame:
Week 52
Reported as:
Number · Participants
Number of Participants Maintaining the ASAS Partial Remission Criteria at Week 52 By Treatment Assignment in the Follow-Up Phase
ParticipantsNaproxenNo Treatment
Achieved Partial Remission1916
Did Not Achieve Partial Remission2124
SecondaryPercentage of Participants Maintaining the ASAS Partial Remission Criteria at Week 52 By Treatment Assignment in the Treatment Phase

ASAS domains were measured on a VAS of 0 to 100 mm (with 0 being the very best situation and 100 being the very worst situation). ASAS partial remission criteria is defined as reaching ≤20 mm in all 4 ASAS domains (i.e., patient global assessment, total back pain, function, and inflammation).

Time frame:
Week 52
Reported as:
Number · Percentage of Participants
Percentage of Participants Maintaining the ASAS Partial Remission Criteria at Week 52 By Treatment Assignment in the Treatment Phase
Percentage of ParticipantsInfliximab + NaproxenPlacebo + Naproxen
Percentage of Participants Maintaining the ASAS Partial Remission Criteria at Week 52 By Treatment Assignment in the Treatment Phase4055
SecondaryChange From Baseline of Berlin Magnetic Resonance Imaging (MRI) Spine Overall Score at Week 28

MRI scans (T1 for chronic changes and short tau inversion recovery \[STIR\] for active changes) of the whole spine was performed to determine the Berlin MRI Spine Score. The Berlin MRI scoring for the spine was assessed on a scale of 0 (best) to 3 (worst) for a maximum total score of 69, with 0 = no inflammatory lesions; 1 = minor bone marrow edema; 2 = moderate bone marrow edema; 3 = major bone marrow edema; or N = non readable.

Time frame:
Baseline, Week 28
Reported as:
Median · Units on a Scale
Change From Baseline of Berlin Magnetic Resonance Imaging (MRI) Spine Overall Score at Week 28
Units on a ScaleInfliximab + NaproxenPlacebo + Naproxen
Change From Baseline of Berlin Magnetic Resonance Imaging (MRI) Spine Overall Score at Week 28-0.5 (-3.5 to 0.0)0.0 (-4.7 to 0.0)
SecondaryChange From Baseline in the Sacroiliac Overall Score at Week 28

Each sacroiliac joint was divided into four quadrants. An activity score of 0 (best) to 3 (worst) was assessed for every quadrant of the left and right sacroiliac joint separately for a total maximum score of 24, with with 0 = no inflammatory lesions; 1 = minor bone marrow edema; 2 = moderate bone marrow edema; 3 = major bone marrow edema; or N = non readable.

Time frame:
Baseline, Week 28
Reported as:
Median · Units on a Scale
Change From Baseline in the Sacroiliac Overall Score at Week 28
Units on a ScaleInfliximab + NaproxenPlacebo + Naproxen
Change From Baseline in the Sacroiliac Overall Score at Week 28-2.0 (-7.0 to -0.5)-3.0 (-6.5 to -1.0)
SecondaryChange From Baseline of Berlin MRI Spine Overall Score at Week 52

MRI scans (T1 for chronic changes and STIR for active changes) of the whole spine was performed to determine the Berlin MRI Spine Score. The Berlin MRI scoring for the spine was assessed on a scale of 0 (best) to 3 (worst) for a maximum total score of 69, with 0 = no inflammatory lesions; 1 = minor bone marrow edema; 2 = moderate bone marrow edema; 3 = major bone marrow edema; or N = non readable.

Time frame:
Baseline, Week 52
Reported as:
Median · Units on a Scale
Change From Baseline of Berlin MRI Spine Overall Score at Week 52
Units on a ScaleNaproxenNo Treatment
Change From Baseline of Berlin MRI Spine Overall Score at Week 520.0 (0.0 to 1.0)0.0 (0.0 to 2.3)
SecondaryChange From Baseline in the Sacroiliac Overall Score at Week 52

Each sacroiliac joint was divided into four quadrants. An activity score of 0 (best) to 3 (worst) was assessed for every quadrant of the left and right sacroiliac joint separately for a total maximum score of 24, with with 0 = no inflammatory lesions; 1 = minor bone marrow edema; 2 = moderate bone marrow edema; 3 = major bone marrow edema; or N = non readable.

Time frame:
Baseline, Week 28
Reported as:
Median · Units on a Scale
Change From Baseline in the Sacroiliac Overall Score at Week 52
Units on a ScaleNaproxenNo Treatment
Change From Baseline in the Sacroiliac Overall Score at Week 521.1 (0.0 to 4.0)1.0 (0.0 to 3.3)
SecondaryNumber of Participants With Complete Absence of Active Inflammatory Lesions at the Spine at Treatment Week 28

MRI scans (T1 for chronic changes and STIR for active changes) of the whole spine was performed to determine the Berlin MRI Spine Score. The Berlin MRI scoring for the spine was assessed on a scale of 0 (best) to 3 (worst) for a maximum total score of 69, with 0 = no inflammatory lesions; 1 = minor bone marrow edema; 2 = moderate bone marrow edema; 3 = major bone marrow edema; or N = non readable. Complete absence of active inflammatory lesions was defined as a Berlin MRI Score = 0.

Time frame:
Week 28
Reported as:
Number · Participants
Number of Participants With Complete Absence of Active Inflammatory Lesions at the Spine at Treatment Week 28
ParticipantsInfliximab + NaproxenPlacebo + Naproxen
Number of Participants With Complete Absence of Active Inflammatory Lesions at the Spine at Treatment Week 286323
Statistical analysis
  • Infliximab + Naproxen vs Placebo + Naproxen · Fisher Exact · p = =0.0884 · Difference in percentages: 14.9 · 95% CI -1.7 to 31.5The 95% CI for treatment differences were computed using Wilson's Method.
SecondaryNumber of Participants With Complete Absence of Active Inflammatory Lesions at the Sacroiliac Joint at Treatment Week 28

Each sacroiliac joint was divided into four quadrants. An activity score of 0 (best) to 3 (worst) was assessed for every quadrant of the left and right sacroiliac joint separately for a total maximum score of 24, with with 0 = no inflammatory lesions; 1 = minor bone marrow edema; 2 = moderate bone marrow edema; 3 = major bone marrow edema; or N = non readable. Complete absence of active inflammatory lesions at the sacroiliac joints was defined as a Score = 0.

Time frame:
Week 28
Reported as:
Number · Participants
Number of Participants With Complete Absence of Active Inflammatory Lesions at the Sacroiliac Joint at Treatment Week 28
ParticipantsInfliximab + NaproxenPlacebo + Naproxen
Number of Participants With Complete Absence of Active Inflammatory Lesions at the Sacroiliac Joint at Treatment Week 28293
Statistical analysis
  • Infliximab + Naproxen vs Placebo + Naproxen · Fisher Exact · p = =0.0013 · Difference in percentages: 21.7 · 95% CI 11.0 to 32.5The 95% CI for treatment differences were computed using Wilson's Method.
SecondaryNumber of Participants With Complete Absence of Active Inflammatory Lesions at the Spine and Sacroiliac Joint at Treatment Week 28

MRI scans (T1 for chronic changes and STIR for active changes) of the whole spine was performed to determine the Berlin MRI Spine Score. The Berlin MRI scoring for the spine was assessed on a scale of 0 (best) to 3 (worst) for a maximum total score of 69, with 0 = no inflammatory lesions; 1 = minor bone marrow edema; 2 = moderate bone marrow edema; 3 = major bone marrow edema; or N = non readable. Complete absence of active inflammatory lesions was defined as a Berlin MRI Score = 0. Each sacroiliac joint was divided into four quadrants. An activity score of 0 (best) to 3 (worst) was assessed for every quadrant of the left and right sacroiliac joint separately for a total maximum score of 24, with with 0 = no inflammatory lesions; 1 = minor bone marrow edema; 2 = moderate bone marrow edema; 3 = major bone marrow edema; or N = non readable. Complete absence of active sacroiliac inflammatory lesions was defined as a Score = 0.

Time frame:
Week 28
Reported as:
Number · Participants
Number of Participants With Complete Absence of Active Inflammatory Lesions at the Spine and Sacroiliac Joint at Treatment Week 28
ParticipantsInfliximab + NaproxenPlacebo + Naproxen
Number of Participants With Complete Absence of Active Inflammatory Lesions at the Spine and Sacroiliac Joint at Treatment Week 28190
Statistical analysis
  • Infliximab + Naproxen vs Placebo + Naproxen · Fisher Exact · p = =0.0004 · Difference in percentages: 18.1 · 95% CI 10.7 to 25.5The 95% CI for treatment differences were computed using Wilson's Method.
SecondaryNumber of Participants With Complete Absence of Active Inflammatory Lesions at the Spine at Treatment Week 52

MRI scans (T1 for chronic changes and STIR for active changes) of the whole spine was performed to determine the Berlin MRI Spine Score. The Berlin MRI scoring for the spine was assessed on a scale of 0 (best) to 3 (worst) for a maximum total score of 69, with 0 = no inflammatory lesions; 1 = minor bone marrow edema; 2 = moderate bone marrow edema; 3 = major bone marrow edema; or N = non readable. Complete absence of active inflammatory lesions was defined as a Berlin MRI Score = 0.

Time frame:
Week 52
Reported as:
Number · Participants
Number of Participants With Complete Absence of Active Inflammatory Lesions at the Spine at Treatment Week 52
ParticipantsNaproxenNo Treatment
Number of Participants With Complete Absence of Active Inflammatory Lesions at the Spine at Treatment Week 522016
Statistical analysis
  • Naproxen vs No Treatment · Fisher Exact · p = =0.5005 · Difference in percentages: 10.0 · 95% CI -11.7 to 31.7The 95% CI for treatment differences were computed using Wilson's Method.
SecondaryNumber of Participants With Complete Absence of Active Inflammatory Lesions at the Sacroiliac Joint at Treatment Week 52

EaEach sacroiliac joint was divided into four quadrants. An activity score of 0 (best) to 3 (worst) was assessed for every quadrant of the left and right sacroiliac joint separately for a total maximum score of 24, with with 0 = no inflammatory lesions; 1 = minor bone marrow edema; 2 = moderate bone marrow edema; 3 = major bone marrow edema; or N = non readable. Complete absence of active sacroiliac inflammatory lesions was defined as a Score = 0.

Time frame:
Week 52
Reported as:
Number · Participants
Number of Participants With Complete Absence of Active Inflammatory Lesions at the Sacroiliac Joint at Treatment Week 52
ParticipantsNaproxenNo Treatment
Number of Participants With Complete Absence of Active Inflammatory Lesions at the Sacroiliac Joint at Treatment Week 5234
Statistical analysis
  • Naproxen vs No Treatment · Fisher Exact · p = =1.0000 · Difference in percentages: -2.5 · 95% CI -14.9 to 9.9The 95% CI for treatment differences were computed using Wilson's Method.
SecondaryNumber of Participants With Complete Absence of Active Inflammatory Lesions at the Spine and Sacroiliac Joint at Treatment Week 52

MRI scans (T1 for chronic changes and STIR for active changes) of the whole spine was performed to determine the Berlin MRI Spine Score. The Berlin MRI scoring for the spine was assessed on a scale of 0 (best) to 3 (worst) for a maximum total score of 69, with 0 = no inflammatory lesions; 1 = minor bone marrow edema; 2 = moderate bone marrow edema; 3 = major bone marrow edema; or N = non readable. Complete absence of active spinal inflammatory lesions was defined as a Berlin MRI Score = 0. Each sacroiliac joint was divided into four quadrants. An activity score of 0 (best) to 3 (worst) was assessed for every quadrant of the left and right sacroiliac joint separately for a total maximum score of 24, with with 0 = no inflammatory lesions; 1 = minor bone marrow edema; 2 = moderate bone marrow edema; 3 = major bone marrow edema; or N = non readable. Complete absence of active sacroiliac inflammatory lesions was defined as a Score = 0.

Time frame:
Week 52
Reported as:
Number · Participants
Number of Participants With Complete Absence of Active Inflammatory Lesions at the Spine and Sacroiliac Joint at Treatment Week 52
ParticipantsNaproxenNo Treatment
Number of Participants With Complete Absence of Active Inflammatory Lesions at the Spine and Sacroiliac Joint at Treatment Week 5211
Statistical analysis
  • Naproxen vs No Treatment · Fisher Exact · p = =1.0000 · Difference in percentages: 0.0 · 95% CI -6.8 to 6.8The 95% CI for treatment differences were computed using Wilson's Method.
SecondaryMedian Duration of Maintaining ASAS Partial Remission in the Follow-Up Phase

ASAS domains were measured on a VAS of 0 to 100 mm (with 0 being the very best situation and 100 being the very worse situation). ASAS partial remission criteria is defined as reaching ≤20 mm in all 4 ASAS domains (i.e., patient global assessment, total back pain, function, and inflammation).

Time frame:
Week 52
Reported as:
Median · Weeks
Median Duration of Maintaining ASAS Partial Remission in the Follow-Up Phase
WeeksNaproxenNo Treatment
Median Duration of Maintaining ASAS Partial Remission in the Follow-Up Phase23.00 (3.43 to 26.71)12.57 (4.71 to 25.14)
Statistical analysis
  • Naproxen vs No Treatment · Log Rank · p = =0.3802
SecondaryNumber of Participants Who Achieved ASAS Partial Remission That Experienced Disease Flare With Naproxen Maintenance Treatment in the Follow-Up Phase

The Bath Ankylosing Spondylitis Disease Activity Index (BASDAI) employs a VAS of 0mm (best) to 100mm (worst). Disease flare was defined as reaching a BASDAI of ≥30 mm during two consecutive visits after Week 28 until Week 52. ASAS domains were measured on a VAS of 0 to 100 mm (with 0 being the very best situation and 100 being the very worse situation). ASAS partial remission criteria was defined as reaching ≤20 mm in all 4 ASAS domains (i.e., patient global assessment, total back pain, function, and inflammation).

Time frame:
Week 52
Reported as:
Number · Participants
Number of Participants Who Achieved ASAS Partial Remission That Experienced Disease Flare With Naproxen Maintenance Treatment in the Follow-Up Phase
ParticipantsNaproxenNo Treatment
Number of Participants Who Achieved ASAS Partial Remission That Experienced Disease Flare With Naproxen Maintenance Treatment in the Follow-Up Phase13
Statistical analysis
  • Naproxen vs No Treatment · Fisher Exact · p = =0.6153 · Difference in percentages: -5.0 · 95% CI -14.5 to 4.5The 95% CI for treatment differences were computed using Wilson's Method.
SecondaryPercentage of Participants That Achieved ASAS-40 Response at Week 28 in the Treatment Phase

ASAS domains were measured on a VAS of 0 to 100 mm (with 0 being the very best situation and 100 being the very worse situation). ASAS-40 response was defined as ASAS achieving ≥40% improvement in 3 of the 4 domains (patient global assessment, total back pain, function, and inflammation), with an absolute improvement of ≥20 mm and no deterioration in the remaining domain.

Time frame:
Week 28
Reported as:
Number · Percentage of Participants
Percentage of Participants That Achieved ASAS-40 Response at Week 28 in the Treatment Phase
Percentage of ParticipantsInfliximab + NaproxenPlacebo + Naproxen
Percentage of Participants That Achieved ASAS-40 Response at Week 28 in the Treatment Phase7929
Statistical analysis
  • Infliximab + Naproxen vs Placebo + Naproxen · Fisher Exact · p = =0.0263 · Difference in percentages: 18.4 · 95% CI 2.5 to 34.3The 95% CI for treatment differences were computed using Wilson's Method.
SecondaryPercentage of Participants That Achieved ASAS-20 Response at Week 28 in the Treatment Phase

ASAS-20 response was defined as ≥20% improvement in response according to following criteria: • An improvement of ≥20% from baseline and an absolute improvement from baseline of ≥10 mm in at least 3 of the following 4 domains (patient global assessment, pain, function,and inflammation) • Absence of deterioration from baseline (≥20% and an absolute change of ≥10 mm) in the potential remaining domain.

Time frame:
Week 28
Reported as:
Number · Percentage of Participants
Percentage of Participants That Achieved ASAS-20 Response at Week 28 in the Treatment Phase
Percentage of ParticipantsInfliximab + NaproxenPlacebo + Naproxen
Percentage of Participants That Achieved ASAS-20 Response at Week 28 in the Treatment Phase8537
Statistical analysis
  • Infliximab + Naproxen vs Placebo + Naproxen · Fisher Exact · p = =0.3011 · Difference in percentages: 8.4 · 95% CI -6.0 to 22.8The 95% CI for treatment differences were computed using Wilson's Method.

Adverse events

Collected over Up to Week 52.. Non-serious events are listed at a 5% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
Infliximab + Naproxen—6/105 (5.7%)24/105 (22.9%)
Placebo + Naproxen—3/52 (5.8%)8/52 (15.4%)
Naproxen—0/41 (0%)6/41 (14.6%)
No Treatment—3/41 (7.3%)11/41 (26.8%)
Most frequent serious events
Showing 10 of 15
Most frequent serious events
EventInfliximab + NaproxenPlacebo + NaproxenNaproxenNo Treatment
AnaemiaBlood and lymphatic system disorders0/1051/520/411/41
Carcinoma In SituNeoplasms benign, malignant and unspecified (incl cysts and polyps)1/1050/520/411/41
Ovarian Cyst RupturedReproductive system and breast disorders0/1051/520/411/41
Dermatitis AtopicSkin and subcutaneous tissue disorders0/1051/520/411/41
Ankylosing SpondylitisMusculoskeletal and connective tissue disorders0/1051/520/410/41
Chest DiscomfortGeneral disorders1/1050/520/410/41
PneumoniaInfections and infestations1/1050/520/410/41
TuberculosisInfections and infestations1/1050/520/410/41
Hepatic Enzyme IncreasedInvestigations1/1050/520/410/41
Breast CancerNeoplasms benign, malignant and unspecified (incl cysts and polyps)1/1050/520/410/41
Most frequent other events
Most frequent other events
EventInfliximab + NaproxenPlacebo + NaproxenNaproxenNo Treatment
NasopharyngitisInfections and infestations13/1055/524/416/41
BronchitisInfections and infestations0/1050/520/414/41
Abdominal Pain UpperGastrointestinal disorders8/1052/520/410/41
DiarrhoeaGastrointestinal disorders0/1050/523/411/41
RhinitisInfections and infestations0/1050/523/412/41
HeadacheNervous system disorders7/1052/520/410/41
DyspepsiaGastrointestinal disorders3/1053/520/410/41

Baseline characteristics

Age, Continuous
Age, Continuous(years)Infliximab + NaproxenPlacebo + NaproxenTotal
Mean31.7 ± 8.5130.7 ± 7.3431.4 ± 8.12
Sex: Female, Male
Sex: Female, Male(Participants)Infliximab + NaproxenPlacebo + NaproxenTotal
Female331144
Male7240112
08

Study locations

No study locations are listed for this record.

09

References and documents

Publications

  • Sieper J, Lenaerts J, Wollenhaupt J, Rudwaleit M, Mazurov VI, Myasoutova L, Park S, Song Y, Yao R, Chitkara D, Vastesaeger N; All INFAST Investigators. Efficacy and safety of infliximab plus naproxen versus naproxen alone in patients with early, active axial spondyloarthritis: results from the double-blind, placebo-controlled INFAST study, Part 1. Ann Rheum Dis. 2014 Jan;73(1):101-7. doi: 10.1136/annrheumdis-2012-203201. Epub 2013 May 21. PubMed 23696633 ↗
  • Sieper J, Lenaerts J, Wollenhaupt J, Rudwaleit M, Mazurov VI, Myasoutova L, Park S, Song Y, Yao R, Chitkara D, Vastesaeger N; All INFAST Investigators. Maintenance of biologic-free remission with naproxen or no treatment in patients with early, active axial spondyloarthritis: results from a 6-month, randomised, open-label follow-up study, INFAST Part 2. Ann Rheum Dis. 2014 Jan;73(1):108-13. doi: 10.1136/annrheumdis-2013-203460. Epub 2013 Jun 5. PubMed 23740231 ↗
  • Poddubnyy D, Listing J, Sieper J. Brief Report: Course of Active Inflammatory and Fatty Lesions in Patients With Early Axial Spondyloarthritis Treated With Infliximab Plus Naproxen as Compared to Naproxen Alone: Results From the Infliximab As First Line Therapy in Patients with Early Active Axial Spondyloarthritis Trial. Arthritis Rheumatol. 2016 Aug;68(8):1899-903. doi: 10.1002/art.39690. PubMed 27015283 ↗

Individual participant data

Plan to share: Yes — http://www.merck.com/clinical-trials/pdf/Merck%20Procedure%20on%20Clinical%20Trial%20Data%20Access%20Final_Updated%20July_9_2014.pdf http://engagezone.msd.com/ds_documentation.php

10

Timeline

Tracking since Sep 25, 2026
Not marked actual or estimatedDates not marked actual or estimated

The record gives a start of Sep 2009, a primary completion of Apr 2011 and a completion of Sep 2011. It does not say whether these dates are actual or estimated.

Results were first posted in Dec 2012, 1 year 8 months after primary completion.

How these figures are worked out, and which studies are left out of them.

Registered
Feb 13, 2009
First posted
Feb 16, 2009
Start
Sep 2009
Primary completionActual
Apr 2011
CompletionActual
Sep 2011
Results first posted
Dec 17, 2012
Last update
Apr 12, 2017
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Apr 12, 2017, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
11

Registry details

Key details

Study ID
NCT00844805
Responsible party
Sponsor
First posted
Feb 16, 2009
Start date
Sep 2009
Primary completion
Apr 2011
Completion
Sep 2011
Results posted
Dec 17, 2012
Last update
Apr 12, 2017

Oversight

Data monitoring committee
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Mar 2017. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drugs tested here: Infliximab · Naproxen

Start the discussion